Health-Related Quality of Life After Transcatheter Aortic Valve Replacement in Inoperable Patients With Severe Aortic Stenosis

Background- Transcatheter aortic valve replacement (TAVR) has been shown to improve survival compared with standard therapy in patients with severe aortic stenosis who cannot have surgery. The effects of TAVR on health-related quality of life have not been reported from a controlled study. Methods a...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2011-11, Vol.124 (18), p.1964-1972
Main Authors: REYNOLDS, Matthew R, MAGNUSON, Elizabeth A, HERRMANN, Howard C, KAPADIA, Samir, KODALI, Susheel K, MAKKAR, Raj R, PICHARD, Augusto D, COHEN, David J, YANG LEI, LEON, Martin B, SMITH, Craig R, SVENSSON, Lars G, WEBB, John G, BABALIAROS, Vasilis C, BOWERS, Bruce S, FEARON, William F
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Aortic Valve Stenosis - physiopathology
Aortic Valve Stenosis - surgery
Biological and medical sciences
Blood and lymphatic vessels
Cardiac Catheterization
Cardiology. Vascular system
Diseases of the aorta
Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous
Female
Follow-Up Studies
Health Status
Heart Valve Prosthesis Implantation - methods
Humans
Male
Medical sciences
Prospective Studies
Quality of Life
Severity of Illness Index
Surveys and Questionnaires
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background- Transcatheter aortic valve replacement (TAVR) has been shown to improve survival compared with standard therapy in patients with severe aortic stenosis who cannot have surgery. The effects of TAVR on health-related quality of life have not been reported from a controlled study. Methods and Results- The Placement of Aortic Transcatheter Valves (PARTNER) trial randomized patients with symptomatic, severe aortic stenosis who were not candidates for surgical valve replacement to TAVR (n=179) or standard therapy (n=179). Health-related quality of life was assessed at baseline and at 1, 6, and 12 months with the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the 12-item Short Form-12 General Health Survey (SF-12). The primary end point was the KCCQ overall summary score (range, 0-100; higher=better). At baseline, mean KCCQ summary scores (35±20) and SF-12 physical summary scores (28±7) were markedly depressed. Although the KCCQ summary score improved from baseline in both groups, the extent of improvement was greater after TAVR compared with control at 1 month (mean between-group difference, 13 points; 95% confidence interval, 8-19; P
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.111.040022